Follow
C Day
C Day
Verified email at ncl.ac.uk
Title
Cited by
Cited by
Year
Steatohepatitis: a tale of two “hits”?
CP Day, OFW James
Gastroenterology 114 (4), 842-845, 1998
62591998
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD
P Angulo, JM Hui, G Marchesini, E Bugianesi, J George, GC Farrell, ...
Hepatology 45 (4), 846-854, 2007
35302007
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
European Association for the Study of The Liver, ...
Obesity facts 9 (2), 65-90, 2016
25972016
Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease
G Targher, CP Day, E Bonora
New England Journal of Medicine 363 (14), 1341-1350, 2010
23552010
QT dispersion: an indication of arrhythmia risk in patients with long QT intervals.
CP Day, JM McComb, RW Campbell
Heart 63 (6), 342-344, 1990
21061990
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
QM Anstee, G Targher, CP Day
Nature reviews Gastroenterology & hepatology 10 (6), 330-344, 2013
19792013
Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease
L Miele, V Valenza, G La Torre, M Montalto, G Cammarota, R Ricci, ...
Hepatology 49 (6), 1877-1887, 2009
17062009
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
GP Aithal, CP Day, PJL Kesteven, AK Daly
The Lancet 353 (9154), 717-719, 1999
17011999
Modeling nafld disease burden in china, france, germany, italy, japan, spain, united kingdom, and united states for the period 2016–2030
C Estes, QM Anstee, MT Arias-Loste, H Bantel, S Bellentani, J Caballeria, ...
Journal of hepatology 69 (4), 896-904, 2018
16452018
Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients
G Targher, L Bertolini, R Padovani, S Rodella, R Tessari, L Zenari, C Day, ...
Diabetes care 30 (5), 1212-1218, 2007
15342007
Elective surgery cancellations due to the COVID-19 pandemic: global predictive modelling to inform surgical recovery plans
Journal of British Surgery 107 (11), 1440-1449, 2020
15062020
A position statement on NAFLD/NASH based on the EASL 2009 special conference
V Ratziu, S Bellentani, H Cortez-Pinto, C Day, G Marchesini
Journal of hepatology 53 (2), 372-384, 2010
14562010
Mortality after surgery in Europe: a 7 day cohort study
RM Pearse, RP Moreno, P Bauer, P Pelosi, P Metnitz, C Spies, B Vallet, ...
The Lancet 380 (9847), 1059-1065, 2012
14352012
The natural history of nonalcoholic fatty liver: a follow‐up study
MR Teli, OFW James, AD Burt, MK Bennett, CP Day
Hepatology 22 (6), 1714-1719, 1995
12751995
Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis
AM Diehl, C Day
New England Journal of Medicine 377 (21), 2063-2072, 2017
12392017
Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management
S McPherson, T Hardy, E Henderson, AD Burt, CP Day, QM Anstee
Journal of hepatology 62 (5), 1148-1155, 2015
12342015
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
AK Daly, PT Donaldson, P Bhatnagar, Y Shen, I Pe'er, A Floratos, MJ Daly, ...
Nature genetics 41 (7), 816-819, 2009
11842009
Non-alcoholic fatty liver disease: the mist gradually clears
NMW de Alwis, CP Day
Journal of hepatology 48, S104-S112, 2008
10622008
Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease
S McPherson, SF Stewart, E Henderson, AD Burt, CP Day
Gut 59 (9), 1265-1269, 2010
9852010
Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers
IN Guha, J Parkes, P Roderick, D Chattopadhyay, R Cross, S Harris, ...
Hepatology 47 (2), 455-460, 2008
9272008
The system can't perform the operation now. Try again later.
Articles 1–20